Sino Biopharmaceutical Ltd 2022 SR
The report highlights Sino Biopharmaceutical's 2022 ESG performance, focusing on its 'CARE' strategy (Cure, Accessible, Relationship, Environmental). Key achievements include a 16.6% increase in R&D investment to RMB 4.45 billion and the launch of a carbon neutrality planning project. The company successfully treated over 150 million patients cumulatively and achieved zero quality safety incidents or product recalls. It also implemented a comprehensive talent development plan for its 26,272 employees and invested over RMB 66 million in community welfare.
Company: Sino Biopharmaceutical Ltd
Sector: Manufacturing
Country: Hong Kong
Year: 2022
Type: SR
Pages: 55
Back to company
Sino Biopharmaceutical Ltd
ESG Report
The report highlights Sino Biopharmaceutical's 2022 ESG performance, focusing on its 'CARE' strategy (Cure, Accessible, Relationship, Environmental). Key achievements include a 16.6% increase in R&D investment to RMB 4.45 billion and the launch of a carbon neutrality planning project. The company successfully treated over 150 million patients cumulatively and achieved zero quality safety incidents or product recalls. It also implemented a comprehensive talent development plan for its 26,272 employees and invested over RMB 66 million in community welfare.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 27, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Workplace Fatalities
Employees